Clinical and experimental effects of growth hormone secretagogues on various organ systems

Hormone Research

Volumn 51, Issue SUPPL. 3, 1999, Pages 16-20

  Svensson, Johan ^a   Bengtsson, Bengt Åke ^a,b  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Body composition; Growth hormone peptide; Growth hormone secretagogue; Heart; Linear growth; Organ system

Indexed keywords

3 AMINO 3 METHYL N [2,3,4,5 TETRAHYDRO 2 OXO 1 [[2' (1H TETRAZOL 5 YL) 1,1' BIPHENYL 4 YL]METHYL] 1H 1 BENZAZEPIN 3 YL]BUTANAMIDE; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; HEXARELIN; IBUTAMOREN; PROTIRELIN; SOMATOMEDIN C;

BODY COMPOSITION; CATABOLISM; CONFERENCE PAPER; DIET; GLUCOSE HOMEOSTASIS; GROWTH DISORDER; GROWTH HORMONE DEFICIENCY; GROWTH HORMONE RELEASE; GROWTH RATE; HEART FUNCTION; HEART PROTECTION; HORMONE RECEPTOR INTERACTION; HUMAN; NITROGEN URINE LEVEL; OBESITY; PRIORITY JOURNAL;

EID: 0032721706     PISSN: 03010163     EISSN: None     Source Type: Journal    
DOI: 10.1159/000053157     Document Type: Conference Paper

References (38)

1. Raben M: Treatment of a pituitary dwarf with human growth hormone. J Clin Endocrinol Metab 1958;18:901-903.
2. de Boer H, Blok G-J, van der Veen E: Clinical aspects of growth hormone deficiency in adults. Endocr Rev 1995;16:63-86.
3. Rudman D, Feller A, Nagraj H, Gergans GA, Lalitha PY, Goldberg AF, Schlenker RA, Cohn L, Rudman IW, Mattson DE: Effects of human growth hormone in men over 60 years old. N Engl J Med 1990;323:1-6.
4. Johannsson G, Mårin P, Lönn L, Ottosson M, Stenlöf K, Björntorp P, Sjöström L, Bengtsson B-Å: GH treatment of abdominally obese men reduces abdominal fat mass, improves glucose and lipoprotein metabolism, and reduces diastolic blood pressure. J Clin Endocrinol Metab 1997;82:727-734.
5. Horber F, Haymond M: Human growth hormone prevents the protein catabolic side effects of prednisone in humans. J Clin Invest 1990; 86:265-272.
6. Casanueva F, Dieguez C: Growth hormone secretagogues: physiological role and clinical utility. Trends Endocrinol Metab 1999;10:30-38.
7. Smith R, Van der Ploeg L, Howard A, Feighner S, Cheng K, Hickey G, Wyvratt MJ, Fischer M, Nargund R, Patchett A: Peptidomimetic regulation of growth hormone secretion. Endocr Rev 1998;18:621-645.
8. Dickson SL, Luckman SD: Induction of c-fos messenger ribonucleic acid in neuropeptide-Y and growth hormone (GH)-releasing factor neurones in the rat arcuate nucleus following systemic injection of the GH secretagogue, GH-releasing pcptide-6. Endocrinology 1997; 138:771-777.
9. Clark J, Kalra P, Crowley W, Kalra S: Neuropeptide Y and human pancreatic polypeptide stimulate feeding in rats. Endocrinology 1984; 115:427-429.
10. Locke W, Kirgis H, Bowers C, Abdoh A: Intracerebroventricular growth hormone-releasing peptidc-6 stimulates eating without affecting plasma growth hormone responses in rats. Life Sci 1995;56:1347-1352.
11. Okada K, Ishii S, Minami S, Sugihara H, Shibasaki T, Wakabayashi I: Intraventricular administration of the growth hormone releasing peptide KP-102 increases food intake in free-feeding rats. Endocrinology 1996;137:5155-5158.
12. Guan X-M, Yu H, Palyha OC, McKee KK, Feighner SD, Sirinathsinghji DJS, Smith RG, Van der Ploeg LHT, Howard AD: Distribution of mRNA encoding the growth hormone secretagogue receptor in brain and peripheral tissues. Mol Brain Res 1997;48:23-29.
13. Moreno-Reyes R, Kerkhofs ML, Hermite-Balériaux M, Thorner M, Van Cauter E, Copinschi G: Evidence against a role for the growth hormone-releasing peptide axis in human slow-wave sleep regulation. Am J Physiol 1998; 274:E779-E784.
14. Frieboes R-M, Murck H, Maier P, Schier T, Holsboer F, Steiger A: Growth hormone-releasing peptide-6 stimulates sleep, growth hormone, ACTH and cortisol release in normal man. Neuroendocrinology 1995;61:584-589.
15. Copinschi G, Leproult R, Van Onderbergen A, Caufriez A, Cole K, Schilling LM, Mendel CM, De Lepelcire I, Bolognese JA, Van Cauter E: Prolonged oral treatment with MK-0677, a novel growth hormone secretagogue, improves sleep quality in man. Neuroendocrinology 1997;66:278-286.
16. Saccà L, Cittadini A, Fazio S: Growth hormone and the heart. Endocr Rev 1994;15:555-573.
17. Isgaard J, Kujacic V, Jennische E, Holmäng A, Sun XY, Hedner T, Hjalmarson Å, Bengtsson B-Å: Growth hormone improves cardiac function in rats with experimental myocardial infarction. Eur J Clin Invest 1997;27:517-525.
18. De Gennaro Colonna V, Rossoni G, Bernareggi M, Muller E, Berti F: Cardiac ischemia and impairment of vascular endothelium function in hearts from growth hormone-deficient rats: protection by hexarelin. Eur J Pharmacol 1997; 334:201-207.
19. De Gennaro Colonna V, Rossoni G, Bernareggi M, Muller E, Berti F: Hexarelin, a growth hormone-releasing peptide, discloses protectant activity against cardiovascular damage in rats with isolated growth hormone deficiency. Cardiologia 1997;42:1165-1172.
20. Rossoni G, De Gennaro Colonna V, Bernareggi M, Polvani G, Muller EE, Berti F: Protectant activity of hexarelin or growth hormone against postischemic ventricular dysfunction in hearts from aged rats. J Cardiovasc Pharmacol 1998; 32:260-265.
21. Rahim A, O'Neill P, Shalet S: Growth hormone status during long-term hexarelin therapy. J Clin Endocrinol Metab 1998;83:1644-1649.
22. Van den Berghe G, De Zegher F, Baxter R, Veldhuis J, Wouters P, Schetz M, Verwaest C, Van der Vorst E, Lauwers P, Bouillon R, Bowers C: Neuroendocrinology of prolonged critical illness: effects of exogenous thyrotropinreleasing hormone and its combination with growth hormone secretagogues. J Clin Endocrinol Metab 1998;83:309-319.
23. Gertz B, Sciberras L, Yogendran L, Christie K, Bador K, Krupa D, Wittreich J, James I: L-692,429, a nonpeptide growth hormone secretagogue, reverses glucocorticoid suppression of GH secretion. J Clin Endocrinol Metab 1994;79:745-749.
24. Murphy M, Plunkett L, Gertz B, He W, Wittreich J, Polvino W, Clemmons D: MK-0677, an orally active growth hormone secretagogue, reverses diet-induced catabolism. J Clin Endocrinol Metab 1998;83:320-325.
25. Svensson J, Lönn L, Jansson J-O, Murphy G, Wyss D, Krupa D, Cerchio K, Polvino W, Gertz B, Bosæus I, Sjöström L, Bengtsson B-Å: Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-0677 increases GH secretion, fat-free mass, and energy expenditure. J Clin Endocrinol Metab 1998;83:362-369.
26. Lieber R, Jacks T, Mohler R, Schleim K, Haven M, Cuizon D, Gershuni D, Lopez M, Hora DJ, Nargund R, Feeney W, Hickey G: Growth hormone secretagogue increases muscle strength during remobilization after canine hindlimb immobilization. J Orthop Res 1997; 15:519-527.
27. Laron Z, Frenkel J, Deghenghi R, Anin S, Klinger B, Sibergeld A: Intranasal administration of the GHRP hexarelin accelerates growth in short children. Clin Endocrinol 1995;43:631-635.
28. Chapman I, Bach M. Van Cauter E, Farmer M, Krupa D, Taylor A, Schilling L, Cole K, Skiles E, Pezzoli S, Hartman M, Veldhuis J, Gormley G, Thorner M: Stimulation of the growth hormone (GH)-insulin-like growth factor-I axis by daily oral administration of a GH secretagogue (MK-0677) in healthy elderly subjects. J Clin Endocrinol Metab 1996;81:4249-4257.
29. Fowelin J, Attvall S, Lager I, Bengtsson B-Å: Effects of treatment with recombinant human growth hormone on insulin sensitivity and glucose metabolism in adults with growth hormone deficiency. Metabolism 1993;42:1443-1447.
30. Pombo M, Barreiro J, Peñalva A, Peino R, Dieguez C, Casanueva FF: Absence of growth hormone (GH) secretion after the administration of either GH-releasing hormone (GHRH), GH-releasing peptide (GHRP-6), or GHRH plus GHRP-6 in children with neonatal pituitary stalk transection. J Clin Endocrinol Metab 1995;80:3180-3184.
31. Popovic V, Damjanovic S, Mimic D, Djurovic M, Dieguez C, Casanueva F: Blocked growth hormone-releasing peptide (GHRP-6)-induced GH secretion and absence of the synergistic action of GHRP-6 plus GH-releasing hormone in patients with hypothalamopituitary disconnection: evidence that GHRP-6 main action is exerted at the hypothalamic level. J Clin Endocrinol Metab 1995;80:942-947.
32. Thorner M, Rochiccioli P, Colle M, Lanes R, Grunt J, Galazka A, Landy H, Eengrand P, Shah S: Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone deficient children during first year of therapy. J Clin Endocrinol Metab 1996;81:1189-1196.
33. Bowers C, Alster D, Frentz J: The growth hormone-releasing activity of a synthetic hexapeptide in normal men and short statured children after oral administration. J Clin Endocrinol Metab 1992;74:292-298.
34. Klinger B, Silbergeld A, Deghenghi R, Frenkel J, Laron Z: Desensitization from long-term intranasal treatment with hexarelin does not interfere with the biological effects of this growth hormone-releasing peptide in short children. Eur J Endocrinol 1996;134:716-719.
35. Pihoker C, Badger T, Reynolds G, Bowers C: Treatment effects of intranasal growth hormone releasing peptide-2 in children with short stature. J Endocrinol 1997;155:79-86.
36. Mericq V, Cassorla F, Salazar T, Avila A, Iniguez G, Bowers C, Merriam G: Effects of eight months treatment with graded doses of a growth hormone (GH)-releasing peptide in GH-deficient children. J Clin Endocrinol Metab 1998;83:2355-2360.
37. Svensson J, Ohlsson C, Jansson J-O, Murphy G, Wyss D, Krupa D, Cerchio K, Polvino W, Gertz B, Baylink D, Mohan S, Bengtsson B-Å: Treatment with the oral growth hormone secretagogue MK-0677 increases markers of bone formation and bone resorption in obese young males. J Bone Miner Res 1998;13:1158-1166.
38. Svensson J, Lall S, Dickson S, Rømer J, Ahnfelt-Rønne I, Ohlsson C, Jansson J-O: The growth hormone (GH) secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats (abstract). J Bone Miner Res 1999;13(suppl):F235.